SuperworthArq EPS ARQ
Diluted earnings per share by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 30, 2026
- −$1.26
- Latest quarter, Q2 FY26
- −$0.02
- Fiscal year 2025
- −$1.28
Arq's earnings per share was −$1.26 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.02.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.28 | n/a |
| FY2024 | −$0.14 | n/a |
| FY2023 | −$0.49 | n/a |
| FY2022 | −$0.49 | −115% |
| FY2021 | $3.27 | n/a |
| FY2020 | −$1.14 | −159% |
| FY2019 | $1.93 | +10% |
| FY2018 | $1.76 | +36% |
| FY2017 | $1.29 | −70% |
| FY2016 | $4.37 | n/a |
| FY2015 | −$1.38 | −2860% |
| FY2014 | $0.05 | n/a |
| FY2013 | −$1.09 | n/a |
| FY2012 | −$0.65 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.02 | n/a | −$1.26 | |
| Q1 FY26 | −$0.02 | n/a | −$1.30 | |
| Q4 FY25 | −$1.20 | n/a | −$1.28 | |
| Q3 FY25 | −$0.02 | −150% | −$0.11 | |
| Q2 FY25 | −$0.06 | n/a | −$0.05 | |
| Q1 FY25 | $0.00 | n/a | −$0.05 | |
| Q4 FY24 | −$0.03 | −127% | −$0.14 | |
| Q3 FY24 | $0.04 | n/a | $0.00 | |
| Q2 FY24 | −$0.06 | n/a | −$0.11 | |
| Q1 FY24 | −$0.09 | n/a | −$0.26 | |
| Q4 FY23 | $0.11 | n/a | −$0.49 | |
| Q3 FY23 | −$0.07 | n/a | −$0.77 |
Against its peers
Companies in Chemicals nearest Arq's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ARQArq | −$1.26 | |
| FTLFFitlife Brands | $0.62 | −23% a year |
| BTMDbiote | $0.10 | −89% a year |
| NAGENiagen Bioscience | $0.18 | −14% a year |
| Peer median | $0.18 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Arq
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.